Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR

Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY
2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
REGULATED INFORMATION
GHENT, Belgium, 8 July 2014 -Ablynx [Euronext Brussels: ABLX] today announced,
in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the
publication of major shareholdings in issuers whose securities are admitted to
trading on a regulated market (the "Transparency Law"), that it received a
notification of shareholdings from FMR LLC.
The above legal entity informed that it has been granted discretionary power
to vote for more than 3% of Ablynx' voting rights, as it shall exercise voting
rights incorporated in 1,810,500 Ablynx shares, which represent 3.35% of the
current 53,991,659 outstanding shares of Ablynx.
Such voting rights shall be exercised by FMR LLC, which controls the following
companies acting as fund manager for various undertakings for collective
investment, that hold a participation in Ablynx shares: Fidelity Management &
Research Company, Pyramis Global Advisors LLC and Pyramis Global Advisors
Trust Company.
Full versions of all transparency notifications are available on the website
of Ablynx, under the section Investors.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has more than 30 programmes in the pipeline and seven Nanobodies in clinical
development. Ablynx has on-going research collaborations and significant
partnerships with major pharmaceutical companies including AbbVie, Boehringer
Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered
in Ghent, Belgium. More information can be found on www.ablynx.com.
Voor bijkomende informatie, gelieve contact op te nemen met
Ablynx:
Dr Edwin Moses
Gedelegeerd Bestuurder
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Volg ons op Twitter @AblynxABLX
Ablynx media relaties Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
e: ablynx@consilium-comms.com
pdf format of the press release
------------------------------------------------------------------------------
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire
HUG#1818479